Helix BioPharma Corp. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies in Canada. The company faces significant concerns, including a negative return on assets of -153.0% and a low current ratio of 0.42, indicating potential liquidity issues. Additionally, the stock has dropped 13.27% today, reflecting market volatility. While the biotechnology sector offers growth potential, Helix's financial health raises red flags that investors should consider carefully.
Loading financial metrics...
Company has $715K in cash but burned $983K last quarter. At this burn rate, only 0.7 quarters of runway remain without additional financing.
Company posted a loss of $-9.5M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $3.9M over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (April 30, 2025)